旺山旺水－Ｂ 02630Prospectus Information

Prospectus Information
返回 Stock Info Prospectus Allotment Results Allotment Profile Expected Lots
IPO Timeline
Broker Deadline
2025-11-03
Morning deadline
HKEX Deadline
2025-11-03
Noon deadline
Broker Results (T-2)
2025-11-04
Some brokers release in afternoon
Grey Market (T-1)
2025-11-05
Afternoon
HKEX Allotment (T-1)
2025-11-05
Evening
Registrar Allotment (T-1)
2025-11-05
Evening
Listing Day (T)
2025-11-06
First day of trading
Company Overview
Stock Name旺山旺水－Ｂ
Stock Code02630
Company Full Name旺山旺水－Ｂ
IndustryBiotech & Pharma
Principal Activitiesintroduction of our Core Products and VV116: (cid:129) LV232
Listing Date2025-11-06
Listing Rules EraNew Rules (after Aug 2025)
Listing Rules ChapterChapter 18A
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)No. 108, Yuxin Road Suzhou Industrial Park District Suzhou, PRC
Business Address (Hong Kong)香港銅鑼灣勿地臣街1號時代廣場2座31樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.vigonvita.cn
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar ContactComputershare Hong Kong Investor
A-Share/US Dual ListingNo
Offering Information
Offering Mechanism Mechanism B
Offer PriceHK$ 33.37 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 6,673
Par ValueRMB 1.0 / shares
Offer Period2025-10-28 to 2025-11-03
Global Offering Shares17,597,800 shares
HK Public Offer Shares (Initial)1,759,800 shares (10.0%)
Public Offer Lots (Initial)8,799lots (4,399lots, 4,400lots)
International Placing Shares (Initial)15,838,000 shares (90.0%)
Offer Ratio~10.5%
Total Shares Post-IPO167,597,800 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share0%
Clawback Tiers机制B-无回补
Reallocation OptionNo
Total Global Offering SizeHK$ 587,238,586
Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 6,674
2 lots 400 HK$ 13,348
3 lots 600 HK$ 20,022
4 lots 800 HK$ 26,696
5 lots 1,000 HK$ 33,370
6 lots 1,200 HK$ 40,044
7 lots 1,400 HK$ 46,718
8 lots 1,600 HK$ 53,392
9 lots 1,800 HK$ 60,066
10 lots 2,000 HK$ 66,740
15 lots 3,000 HK$ 100,110
20 lots 4,000 HK$ 133,480
25 lots 5,000 HK$ 166,850
30 lots 6,000 HK$ 200,220
35 lots 7,000 HK$ 233,590
40 lots 8,000 HK$ 266,960
45 lots 9,000 HK$ 300,330
50 lots 10,000 HK$ 333,700
75 lots 15,000 HK$ 500,550
100 lots 20,000 HK$ 667,400
125 lots 25,000 HK$ 834,250
150 lots 30,000 HK$ 1,001,100
175 lots 35,000 HK$ 1,167,950
200 lots 40,000 HK$ 1,334,800
225 lots 45,000 HK$ 1,501,650
250 lots 50,000 HK$ 1,668,500
300 lots 60,000 HK$ 2,002,200
350 lots 70,000 HK$ 2,335,900
400 lots 80,000 HK$ 2,669,600
450 lots 90,000 HK$ 3,003,300
500 lots 100,000 HK$ 3,337,000
600 lots 120,000 HK$ 4,004,400
700 lots 140,000 HK$ 4,671,800
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
800 lots 160,000 HK$ 5,339,200
900 lots 180,000 HK$ 6,006,600
1,000 lots 200,000 HK$ 6,674,000
1,250 lots 250,000 HK$ 8,342,500
1,500 lots 300,000 HK$ 10,011,000
1,750 lots 350,000 HK$ 11,679,500
2,000 lots 400,000 HK$ 13,348,000
2,250 lots 450,000 HK$ 15,016,500
2,500 lots 500,000 HK$ 16,685,000
3,000 lots 600,000 HK$ 20,022,000
3,500 lots 700,000 HK$ 23,359,000
4,000 lots 800,000 HK$ 26,696,000
4,399 lots 879,800 HK$ 29,358,926
Valuation & Financials
Market Cap (at Offer Price)HK$ 5,592,738,586
Pre-IPO Valuation (Last Round)To be extracted
P/E Ratio不適用（公司處於虧損狀態）
Profit/Loss StatusNet loss RMB217.6 million
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day Performance
First Day CloseHK$ 82.0
First Day OpenHK$ 95.0
First Day Change145.73%
First Day Volume5534410.0
First Day Turnover486174000.0
Use of Proceeds
Use of Proceeds1、38.0%（或約198.0百萬港元）將用于我們核心產品的研發； 2、27.0%（或約140.7百萬港元）將用于我們其他候選產品的研發； 3、10.0%（或約52.1百萬港元）將用于建設我們的青島工廠； 4、15.0%（或約78.2百萬港元）將用于強化我們的銷售及營銷能力； 5、10.0%（或約52.1百萬港元），將用于營運資金及其他一般公司用途。
Underwriting Syndicate
Sole Sponsor (1)
中信证券（香港）有限公司 CE AAK249(sole)
Sponsor cum Overall Coordinator (1)
中信里昂证券有限公司 CE AAB893
Overall Coordinators (4)
中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 农银国际融资有限公司 CE AWL249 中国银河国际证券（香港）有限公司 CE AXM459
Joint Global Coordinators (4)
中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 农银国际融资有限公司 CE AWL249 中国银河国际证券（香港）有限公司 CE AXM459
Joint Bookrunners (9)
中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 农银国际融资有限公司 CE AWL249 中国银河国际证券（香港）有限公司 CE AXM459 建银国际金融有限公司 CE AJO225 中国光大证券（香港）有限公司 CE AAW536 富途证券国际（香港）有限公司 CE AZT137 老虎证券（香港）环球有限公司 CE BMU940 中泰国际证券有限公司 CE BAA855
Joint Lead Managers (9)
中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 农银国际证券有限公司 CE ACX411 中国银河国际证券（香港）有限公司 CE AXM459 建银国际金融有限公司 CE AJO225 中国光大证券（香港）有限公司 CE AAW536 富途证券国际（香港）有限公司 CE AZT137 老虎证券（香港）环球有限公司 CE BMU940 中泰国际证券有限公司 CE BAA855
Capital Market Intermediaries (10)
中信里昂证券有限公司 CE AAB893 中国国际金融香港证券有限公司 CE AEN894 农银国际融资有限公司 CE AWL249 农银国际证券有限公司 CE ACX411 中国银河国际证券（香港）有限公司 CE AXM459 建银国际金融有限公司 CE AJO225 中国光大证券（香港）有限公司 CE AAW536 富途证券国际（香港）有限公司 CE AZT137 老虎证券（香港）环球有限公司 CE BMU940 中泰国际证券有限公司 CE BAA855
Service Providers
RoleInstitution
Legal Advisor to Company 美迈斯律师事务所
君合律师事务所
竞天公诚律师事务所
Legal Advisor to Sponsors/Underwriters 苏利文•克伦威尔律师事务所（香港）有限法律责任合伙
金杜律师事务所
Auditor and Reporting Accountant 德勤•关黄陈方会计师行
Industry Advisor 灼识行业咨询有限公司
Compliance Advisor 新百利融资有限公司 CE BAU754
Receiving Banks 中国银行（香港）有限公司
中信银行（国际）有限公司
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
ChairmanDr. Tian Guanghui
Company SecretaryMs. Guo Ting
執行董事 (2)
#NameEnglish NameType
1 田广辉 — 執行董事
2 胡天文 — 執行董事
非執行董事 (1)
#NameEnglish NameType
1 刘浩轩 — 非執行董事
獨立非執行董事 (6)
#NameEnglish NameType
1 鞠佃文 — 獨立非執行董事
2 曹新文 — 獨立非執行董事
3 徐宏喜 — 獨立非執行董事
4 杨汝磊 — 獨立非執行董事
5 周洪举 — 獨立非執行董事
6 李建 — 獨立非執行董事
Major Shareholders
Major Shareholders & HoldingsSUBSTANTIAL SHAREHOLDERS So far as our Directors are aware, immediately following the completion of the Global Offering and without taking into account any H Shares which may be issued pursuant to the exercise of the Over-allotment Option, the following persons will have an
AI AI Analysis
!
The following content is generated by an AI model based on historical IPO data. It does NOT constitute investment advice, solicitation, or recommendation. Past subscription patterns and post-listing performance do not guarantee future results. Data may contain inaccuracies — always verify against official HKEX filings and prospectuses before making any investment decision.

Market Sentiment

The IPO saw extraordinary market enthusiasm with an oversubscription ratio of 6238.42x, indicating intense demand for the shares. The overall hit rate of just 3.32% reflects a very low allocation probability for retail investors, typical of highly sought-after biotech listings under Chapter 18A. Final pricing at HK$33.37 likely captured strong institutional interest, though the absence of an indicative range limits pricing insight. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

Tier-specific allocation data is not provided, preventing any analysis of distribution patterns or potential anomalies such as 甲尾-乙头 inefficiencies. Without detailed breakdowns of lots applied and allocated per tier, it is impossible to assess broker fee efficiency or unusual winner ratios at key thresholds. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

The demographic data for this IPO is not available; all recorded percentages for mainland and Hong Kong participation show zero, likely indicating missing or unreported figures. Consequently, no conclusions can be drawn about regional concentration, gender distribution, or Mainland China participation rates. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

AI-generated content. For informational purposes only. Not financial advice. Verify against official sources.
Offering Structure
Subscription Tiers
IPO Timeline
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics